Imidazolylpropylguanidines derived from impromidine and arpromidine are more potent and efficacious agonists at the guinea pig histamine H 2 receptor (gpH 2 R) than at the human H 2 R (hH 2 R) in the GTPase assay. Additionally, such guanidines are histamine H 1 receptor (H 1 R) antagonists with preference for the human relative to the guinea pig receptor. The purpose of this study was to examine structure-activity relationships of guanidines at human and guinea pig H 1 R and H 2 R species isoforms expressed in Sf9 insect cells. Three impromidine analogues and six arpromidine analogues exhibited agonistic activity at H 2 R and antagonistic activity at H 1 R as assessed in the steady-state GTPase assay. Species selectivity of derivatives was similar as compared with the parent compounds. None of the structural modifications examined (different aromatic ring systems and different ring substituents) was superior in terms of H 2 R potency and efficacy relative to impromidine and arpromidine, respectively. These data point to substantial structural constraints at the agonist binding site of H 2 R. Guanidines exhibited distinct structure-activity relationships for H 1 R antagonism in a radioligand competition binding assay and the GTPase assay and for H 1 R inverse agonism. Our data indicate that it is difficult to obtain guanidine-type agonists with high potency and high efficacy for hH 2 R, but those compounds may be useful tools for exploring the antagonist binding site and constitutive activity of H 1 R.
Introduction
Histamine (HA, 1) exerts its biological effects through four receptor subtypes, designated as H 1 , H 2 , H 3 , and H 4 receptors (H 1 R, H 2 R, H 3 R, H 4 R), respectively [1 -3] . The H 1 R couples to G q -proteins, the H 2 R couples to G s -proteins, and the H 3 R and H 4 R couple to G i /G o -proteins. We are particularly interested in the development of H 2 R agonists that could be used for the treatment of acute heart failure, acute promyelocytic leukemia, and inflammatory diseases [4, 5] . H 2 R agonists are divided into two classes. The first class comprises small molecules related to HA 1 ( Fig. 1 ) such as amthamine and dimaprit. The amino group of HA forms an ionic interaction with Asp-98 in transmembrane domain 3, and the imidazole ring interacts with Tyr-182 and Asp-186 in transmembrane domain 5 [6, 7] . The second class of H 2 R agonists consists of longchained and more bulky molecules, impromidine (IMP, 2) and arpromidine (ARP, 6) ( Fig. 1) being the prototypes [4, 8] . Highest potency is found for compounds with a three-membered instead of a two-membered carbon chain as in histamine connecting the imidazole ring and the basic group. The corresponding partial structures of impromidine and histamine are considered as functionally equivalent groups that are important for the receptor activation i. e., the guanidino group and the imidazolylpropyl moieties of IMP and ARP are supposed to form similar interactions with the H 2 R as the amino group and imidazole groups of HA, respectively [5, 9] . Additionally, the 2-(5-methylimidazol-4-ylmethylthio)ethyl moiety of IMP and the 3-(4-fluorophenyl)-3-(2-pyridyl)propyl substituent of ARP interact with a pocket formed by multiple residues in transmembrane domains 3, 6, and 7 [9] . Traditionally, measurement of positive chronotropic effects in the guinea pig right atrium has been used as a read-out for the measurement of H 2 R agonist potency and efficacy [1, 2, 4] . However, recent studies have revealed substantial pharmacological differences between hH 2 R and gpH 2 R recombinantly expressed in Sf9 insect cells [9, 10] . Specifically, at gpH 2 R, IMP and ARP are full agonists and up to 30-fold more potent than HA. In contrast, at hH 2 R, IMP and ARP are only partial agonists and just sixfold more potent than HA [9, 10] . Modeling and mutagenesis studies showed that the pharmacological differences between hH 2 R and gpH 2 R are due to the non-conserved Asp-271 in transmembrane domain 7 of gpH 2 R (Ala-271 in hH 2 R) and Tyr-17 in transmembrane domain 1 of gpH 2 R (Cys-17 in hH 2 R). In addition, IMP and ARP-derived compounds are H 1 R antagonists with preference for gpH 1 R relative to hH 1 R, Asn-84 in transmembrane domain 2 playing a crucial role in conferring speciesselectivity to H 1 R ligands [11, 12] . Our long-term goal is to obtain highly potent and efficacious hH 2 R agonists. The purpose of this study was to extend the structure-activity relationships for IMPderived guanidines 2-5 and ARP-derived guanidines 6 -12 (Scheme 1) for agonistic activity at hH 2 R and gpH 2 R and antagonistic activity at hH 1 R and gpH 1 R. In case of H 2 R, fusion proteins of the receptor and short splice variant of G sa protein (hH 2 R-G saS and gpH 2 R-G saS ) were used to determine agonist-stimulated high-affinity GTP hydrolysis with high sensitivity [9, 10] . In case of H 1 R, we measured GTPase activity of the receptor coupled to insect cell G q -proteins, enhancing the signal with regulator of Gprotein signaling (RGS) proteins [11, 13] .
Results and discussion
Chemistry The guanidine-type histamine H 2 R agonists were accessible according to the synthetic pathways outlined in Scheme 1 following the procedures described for 2 -10 [14 -17] . The guanidines 11 and 12 [18] were synthesized via the corresponding Boc-protected guanidines by stepwise aminolysis of tert-butyl diphenoxymethylidenecarbamate as reported for structurally related alkyl guanidine-N-carboxylates [19] , followed by deprotection with hydrochloric acid. The pertinent phenyl(thiazol-2-yl)propylamines were prepared from the corresponding phenyl(thiazol-2-yl)ketones in analogy to a previously described method [20] .
Pharmacology
Analysis of the interaction of histamine and guanidines 2-12 with hH 2 R-G saS and gpH 2 R-G saS HA activated the GTPase activity of hH 2 R-G saS and gpH 2 R-G saS with similar potency and was a full agonist (Table 1) . IMP 2 activated hH 2 R-G saS with a l sixfold higher potency than HA and was a strong partial agonist. Substitution of the methylimidazolyl moiety of IMP 2 by thiophene 3 slightly reduced efficacy but not potency. The introduction of a phenyl ring 4 reduced the potency and efficacy, whereas a pyridyl ring 5 reduced only potency. At gpH 2 R-G saS , IMP and its derivatives 2-5 were all more potent and efficacious than at hH 2 R-GsaS. The various ring substitutions had no effect on efficacy but similar to hH 2 R-G saS , introduction of a phenyl ring 4 or pyridyl ring 5 reduced potency.
At hH 2 R-G saS , ARP, bearing a 4-fluorophenyl group 6, was similarly potent and efficacious as IMP 2. Extension of the chain length in 6, resulting in the higher homologue 7, reduced both potency and efficacy. Substitution of the pyridyl ring against phenyl 8 slightly increased efficacy but reduced potency. Substitution of the additional phenyl ring with 4-fluoro ( 8 9 cacy with a small effect on potency. Substitution of the 4-fluorophenyl group of ARP 6 with 3,4-dichlorophenyl 10 had a negative impact in terms of potency and efficacy. Among ARP derivatives substituted with a thiazole ring 11, 12, 3,4,5-trichloro-and 4,5-dichloro substitutions were unfavorable in terms of agonist potency and efficacy. At gpH 2 R-G saS , ARP 6 was slightly less potent than IMP 2 but similarly efficacious. Potencies and efficacies of ARPderived guanidines 7-12 were higher at gpH 2 R-G saS than at hH 2 R-G saS . The substitutions in 7, 11, and 12 that exhibited a negative impact on efficacy at hH 2 R-G saS also had a negative impact on efficacy at gpH 2 R-G saS . Similarly to the observations made for hH 2 R-G saS , ARP-derived guanidines 7-12 were less potent than the parent compound 6.
Analysis of the effects of histamine and guanidines at hH 1 R and gpH 1 R The interaction of ligands with H 1 R was examined in a radioligand competition assay, using the antagonist [ 3 H]mepyramine as probe. Guanidine 6 (ARP) exhibited the highest affinity for hH 1 R among all compounds examined ( Table 2 ). The affinity of ARP for hH 1 R surpassed the affinity of HA by almost sixfold. Among ARP derivatives, extension of the connecting chain in 6 by one methylene group 7 had the most pronounced negative impact on affinity. IMP and its analogue 3 showed up to fivefold lower affinity for hH 1 R than HA.
The affinities of all ligands studied were significantly different at hH 1 R and gpH 1 R. HA exhibited a lower affinity for gpH 1 R than for hH 1 R, whereas the opposite was true for guanidines 2, 3, 6, 7, 9, and 10. Among the compounds studied, ARP showed the highest affinity for gpH 1 R, being 150-fold more potent than HA. All substitutions examined in guanidines (2 versus 3 and 6 versus 7, 9, and 10) reduced affinity for gpH 1 R. Like ARP 6, guanidine 9 exhibited substantial selectivity for gpH 1 R relative to hH 1 R, whereas species-selectivity for 3 and 7 was just twofold.
In a recent study, we showed that N G -acylated imidazolylpropylguanidines are potent hH 2 R-and gpH 2 R agonists and partial hH 1 R agonists [10] . These data prompted us to address the question whether IMP-and ARP-derived guanidines exhibit agonistic effects at hH 1 R as well. However, agonistic activity of guanidines at hH 1 R was only minimal for compound 3 and virtually absent for 4 and 11 (Table 3) . Intriguingly, for 6, 7, and 9, inverse agonistic activity was detected as reflected by a decrease of basal GTPase activity. At gpH 1 R, 3 lacked agonistic activity, but similarly to the data obtained with hH 1 R, 6, 7, and 9 showed inverse agonistic activity at gpH 1 R. Compound 9 reduced basal GTP hydrolysis in membranes expressing gpH 1 R with an IC 50 value of 84 l 12 nM (n = 3). This value is consistent with the K B value determined in functional competition experiments of 9 with HA (see below). Moreover, the neutral antagonist 3 (10 lM) shifted the IC 50 of 9 to 1.5 l 0.2 lM (n = 3). Collectively, our data corroborate the notion that hH 1 R exhibits constitutive, i. e. agonistindependent, activity and that several guanidines are inverse H 1 R agonists [11] .
Finally, we also examined the antagonistic effects of guanidines in a functional assay, determining inhibition of HA-stimulated high-affinity GTP hydrolysis (Table 3) . Similar to the data obtained in the radioligand competition assay, ARP 6 exhibited the highest affinity for hH 1 R among all guanidines studied. Except for the higher homologue 7, ARP derivatives exhibited lower antagonistic potency at hH 1 R than the parent compound. The IMP derivatives 3 and 4 showed low antagonistic affinity for hH 1 R as well. With respect to gpH 1 R, ARP 6 was the most potent antagonist as well. The structural variations in 7 and 9 had little impact on antagonist potency, but substitution of the phenyl ring with chlorine 10, 11 had a negative impact on antagonist affinity. IMP derivatives 3 and 4 exhibited about 10-fold lower antagonistic potency than ARP at gpH 1 matory diseases [4, 5] . In order to come closer to these ambitious goals, it is necessary to develop highly potent and efficacious hH 2 R agonists. While initial studies with the guinea pig atrium showed that the guanidines IMP 2 and particularly ARP 6 are highly potent H 2 R agonists [4, 8] , subsequent studies with human cell systems were rather disappointing since IMP and ARP showed reduced efficacy and potency compared to the guinea pig atrium [21, 22] . The unfavorable pharmacological properties of the available H 2 R agonists in human systems substantially delayed the further development of agonists, particularly because the molecular basis for the apparent pharmacological difference between hH 2 R and gpH 2 R remained elusive. Finally, with a lag period of almost a decade, it became clear that two defined amino acid differences in transmembrane domains 1 and 7 between hH 2 R and gpH 2 R account for the pharmacological differences [9] . These advances rekindled interest in the development of H 2 R agonists [5, 10] .
ARP, bearing a 4-fluorophenyl group at the guanidino group, is one of the most potent hH 2 R agonists known so far, but it is still only a partial agonist and less potent than at gpH 2 R (Table 1) [9] . Since substitution of 4-fluorophenyl by 4-chloro and 4-bromo slightly enhanced potency [9] , we explored several halogen ring substitutions in our present study. Unfortunately, various modifications including introduction of a second 4-fluorophenyl group 9 and introduction of a 3,4-dichloro-or a 3,4,5-trichlorophenyl group 10 -12 had negative rather than positive effects on agonist potency and efficacy at hH 2 R. However, this result was not completely unexpected since a 3,4-difluoro substitution also slightly reduced agonist potency at hH 2 R [9] . Other modifications such as substitution of pyridyl by phenyl 6, 8 increased efficacy, but only at the expense of potency. The newly introduced modifications 8 -12 in ARP did not enhance potency and efficacy at gpH 2 R either. At gpH 2 R, ARP derivatives studied were more potent and efficacious than at hH 2 R, pointing to a systematic difference in interaction of agonists with the receptor in the two species. Only with respect to efficacy of 8, there was no statistically significant difference between hH 2 R and gpH 2 R and no compound showed preference for hH 2 R relative to gpH 2 R.
The situation regarding structural modifications using IMP as starting point was similar to what we observed for the ARP series. Specifically ring substitutions in IMP (thiophene, phenyl, and pyridyl) 3 -5 were not advantageous with respect to potency at hH 2 R and gpH 2 R. Additionally, the ring substitutions did not increase but rather tended to decrease agonist efficacy at hH 2 R and gpH 2 R. Although, on first glance, these results may seem disappointing, the data are actually very helpful for future ligand design. Specifically, our results clearly point to substantial structural constraints in the agonistbinding site both in hH 2 R and gpH 2 R. As a consequence of our data, it is probably not a promising strategy to further introduce gradual structural changes in the aromatic ring substituents of guanidines in order to obtain highly potent and efficacious hH 2 R agonists. Rather, future studies should examine more drastic structural changes such as the introduction of saturated ring systems. Based on the present data, it is evident that the Steady-state GTPase activity in Sf9 membranes expressing hH 1 R and gpH 1 R in the presence of the RGS proteins 4 or 19 was determined as described in Experimental (section 3). Reaction mixtures contained HA (1 lM) and guanidines at concentrations from 1 nM to 100 lM as appropriate to generate saturated inhibition curves. Data were analyzed by non-linear regression and were best fit to sigmoid concentration/response curves. Typical basal GTPase activities ranged between l1.5 -2.5 pmol/mg/min, and the maximum stimulatory effect of histamine (100 lM) amounted to 125 -175% above basal. The efficacy (E max ) of histamine was set 1.00. The E max values of other compounds (examined at a fixed concentration of 10 lM) were referred to this value. Data shown are the means l SD of 5 -8 experiments performed in duplicates each. a) p a 0.05 for comparison of hH 1 R and gpH 1 R.
achievement of the long-term goal, i. e. the availability of highly potent and efficacious hH 2 R agonists, is difficult. Probably, the most efficient strategy will be to perform parallel molecular modeling, compound synthesis, and site-directed mutagenesis studies to fully understand the molecular mechanisms of agonist / H 2 R interactions. The detailed analysis of other H 2 R species isoforms including those of rat and dog [1, 2] , will be very informative in this respect, too. Moreover, there are a number of amino acid differences between hH 2 R and gpH 2 R in the N-terminus, the second intracellular loop, and the C-terminus which could contribute to differences in agonist binding and/or G-protein coupling [9] . Understanding the functional relevance of these structural differences between receptor isoforms will be important for future agonist synthesis as well. ARP-derived guanidines but not IMP-derived guanidines are also moderately potent H 1 R antagonists (Tables  2 and 3 ). These data show that H 1 R readily accommodates the second aromatic ring system present in ARP derivatives and that interaction of the aromatic rings with H 1 R contributes substantially to antagonist-affinity. In terms of potential therapeutic application of ARP derivatives for inflammatory diseases, H 1 R antagonism is actually an interesting property since H 2 R agonism and H 1 R antagonism should result in at least additive anti-inflammatory effects [1, 2, 21] . The gpH 2 R shows a three-to fivefold higher affinity for guanidines than hH 2 R (Table 1) , but for H 1 R species isoforms, the affinity difference varies from 1.5-to 10-fold (Tables 2 and 3 ). These data show that the specific aromatic ring systems and their substituents have a much greater impact on H 1 R-than H 2 R-affinity. Most notably, 10, bearing a phenyl-and a 3,4-dichlorophenyl group, exhibits very similar affinity at hH 1 R and gpH 1 R, whereas 9, bearing two 4-fluorophenyl groups, exhibits 10-fold preference for gpH 1 R compared to hH 1 R. Thus, ARP-derived guanidines may become very valuable tools to explore the antagonist binding site of H 1 R.
In this context, it should be noted that the antagonist affinity ratios for the hH 1 R species isoforms in the [ 3 H]mepyramine competition binding assay and the GTPase inhibition assay show some differences (Tables 2  and 3 ). For example, in the competition binding assay, 8 exhibits similar affinity at both receptor isoforms, whereas in the GTPase inhibition assay, the affinity-difference is more than fourfold. A possible explanation for these differences is that the two assays assess different H 1 R populations with different ligand affinities, i. e. the [ 3 H]mepyramine-bound H 1 R (competition binding assays) and the HA-bound H 1 R (GTPase inhibition assay). Thus, guanidines may also become valuable tools to explore multiple ligand-specific H 1 R conformations. The usefulness of guanidines for the exploration of ligand-specific H 2 R conformations was already established in a previous study [9] .
A last aspect that needs to be discussed concerns the constitutive, i. e. agonist-independent, activity of the H 1 R. It is known that several H 1 R antagonists act as inverse agonists as is reflected by a decrease in basal G-protein activity [11, 23] . However, to this end, specific structureactivity relationships for inverse agonistic activity have remained largely unexplored. Our present study shows that IMP derivatives 3, 4 lack inverse agonistic H 1 R activity, whereas certain ARP derivatives 6, 7, 9 clearly display inverse agonism (Table 3 ). These data indicate that two aromatic ring systems at the guanidino group are required for inverse agonism. However, ARP derivatives 10 and 11 lacked inverse agonistic activity. An important difference between the latter two ARP derivatives and the former ARP derivatives is that 6, 7, and 9 bear a fluorophenyl substituent, whereas 10 and 11 bear chlorophenyl substituents. Thus, ARP-derived guanidines will also help us elucidate the structural requirement for inverse agonism at H 1 R and explore the possible physiological function of H 1 R constitutive activity. The guanidines 2 -10 were synthesized as described elsewhere [4, 14 -17] , the compounds 11, 12 were prepared by analogy with known procedures as outlined below. The purity of the pharmacologically investigated compounds was F 98% unless otherwise indicated, as determined by high-performance liquid chromatography or capillary electrophoresis according to previously described methods [24, 25] . propylamine were prepared from the corresponding aromatic ketones via condensation with diethyl cyanomethanephosponate and stepwise reduction of the double bond and the nitrile group; see procedure described in [19] . The pertinent amine (2 mmol) and diphenoxymethylenecarbamic acid t-butyl ester (626 mg, 2 mmol) were stirred in acetonitrile (10 mL) for 10 min. After addition of 3-(1H-imidazol-4-yl)propylamine (250 mg, 2 mmol) the mixture was heated to reflux for 3 -5 h (control by TLC). The solution was evaporated in vacuo, the residue was taken up in 20 mL of 5% acetic acid, phenol was removed by extraction with diethyl ether, and after basification with aqueous ammonia the intermediate, the corresponding guanidine-N-carboxylic acid t-butyl ester, was extracted with methylene chloride and isolated chromatographically from the dried (Na 2 SO 4 ) and evaporated organic layer (Chromatotron, eluent: CHCl 3 then CHCl 3 /MeOH 1 : 1, NH 3 atmosphere). 
Construction of baculoviruses encoding hH 2 R-G saS , gpH 2 R-G saS , hH 1 R, and gpH 1 R was described previously [9] . Baculoviruses encoding RGS proteins 4 and 19 were a gift from Dr. E. Ross (Department of Pharmacology, University of Southwestern Medical Center, Dallas, TX, USA). Sources of other materials are described elsewhere [9, 13] . Baculovirus infection and culture of Sf9 cells and membrane preparation were performed as described [9] . H 2 R-G sa expression levels were 5 -6 pmol/mg as assessed by immunoblotting using the M1 monoclonal antibody and b 2 -adrenoceptor expressed at defined levels as standard [9] . H 1 R expression levels were 4 -6 pmol/mg as assessed by [ 3 H]mepyramine saturation binding [11] .
Steady-state GTPase activity assay GTP hydrolysis in Sf9 membranes expressing H 2 R-G sa fusion proteins or H 1 R isoforms plus RGS proteins was determined as described previously [9, 11] . In brief, assay tubes (100 lL) contained Sf9 membranes (10 lg of protein/tube), various ligands, 1.0 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 lg creatine kinase, and 0.2% (w/v) bovine serum albumin (BSA) in 50 mM Tris/HCl, pH 7.4, and [c -32 P]GTP (0.2 -0.5 lCi/tube). Reactions were conducted for 20 min at 258C and terminated by the addition of 900 lL slurry consisting of 5% (w/v) activated charcoal and 50 mM NaH 2 PO 4 , pH 2.0. 32 P i in supernatant fluids of reaction mixtures was determined by liquid scintillation counting. membranes expressing hH 1 R or gpH 1 R plus RGS proteins were performed as described previously [11] . In brief, assay tubes (500 lL) contained membranes (20 -25 lg of protein/tube), 2 nM [ 3 H]mepyramine and unlabeled ligands in binding buffer (12.5 mM MgCl 2 , 1 mM EDTA and 75 mM Tris/HCl, pH 7.4). Bound radioligand was separated from free radioligand by filtration through GF/C filters, and filter-bound radioactivity was determined by liquid scintillation counting.
Radioligand binding assay

Miscellaneous
Protein concentrations were determined using the Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA, USA). All analyses of experimental data were performed with the Prism 4.02 software (GraphPad-Prism, San Diego, CA, USA). K i and K B values were calculated using the Cheng and Prusoff equation [26] . Statistical comparisons were performed with the t-test.
